Pfizer Stock: Is Wall Street Bullish or Bearish?

Core Insights - Pfizer Inc. has a market cap of $139.3 billion and operates in various therapeutic areas including oncology, inflammation, and cardiovascular health [1] Performance Overview - Pfizer's stock has underperformed the broader market, declining 15.1% over the past year, while the S&P 500 Index has increased by 18.3% [2] - Year-to-date in 2025, Pfizer's stock is down 7.7%, contrasting with the S&P 500's rise of 17.2% [2] - Compared to the Invesco Pharmaceuticals ETF, which gained 8.9% over the past year, Pfizer's performance remains weak [3] Financial Results - In Q2, Pfizer's stock rose 5.2% after reporting earnings that exceeded expectations, with revenue increasing by 10.3% year-over-year to $14.7 billion, surpassing estimates by 6.3% [4] - Adjusted EPS for Q2 rose 30% year-over-year to $0.78, beating analyst forecasts by 34.5% [4] - Pfizer raised its 2025 adjusted EPS guidance to a range of $2.90 to $3.10, which has positively influenced investor sentiment [4] Analyst Ratings - For the current fiscal year ending in December, analysts project a 1.6% decline in EPS to $3.06 on a diluted basis [5] - Pfizer has a strong earnings surprise history, beating consensus estimates in the last four quarters [5] - Among 24 analysts, the consensus rating for Pfizer stock is a "Moderate Buy," with ratings including six "Strong Buy," one "Moderate Buy," 16 "Holds," and one "Strong Sell" [5] Price Targets - Berenberg Bank analyst maintained a "Hold" rating on Pfizer with a price target of $25, indicating a potential upside of 2% from current levels [6] - The mean price target is $28.48, suggesting a 16.2% premium to current prices, while the highest target of $34 indicates a potential upside of 38.8% [6]